Evidence map›Paper›PMID 34402263›Full record

ReviewZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2021

Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma.

Jingyi Hu, Qingqing Wang, Yang Liu

Open access · greenAbstract readReview
In one paragraph

Review in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jingyi HuInstitute of Immunology.
Qingqing WangInstitute of Immunology.
Yang LiuInstitute of Immunology.
Institute of Immunology · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteasome is the eukaryotic organelle responsible for degradation of short-lived proteins and involved in maintaining cellular protein homeostasis. It has been reported that during the occurrence and development of hepatocellular carcinoma (HCC), the regulatory particle subunits of proteasome regulate a series of tumor-related proteins, and proliferation, survival-associated signaling molecules, including PTEN gene, P53, Bcl-2, Bcl-2 interacting mediator of cell death (Bim), cyclin-dependent kinase 4(CDK4), transforming growth factor β receptor (TGFBR), E2F1, growth factor receptor-bound protein 2 (GRB2) . Meanwhile, these subunits regulate some tumor-associated pathway protein, such as signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT), inducing their malfunction to promote the occurrence, proliferation, invasion and metastasis of HCC. The core particle subunits are more to perform the degradation of HCC-related proteins, so inhibitors targeting the core particle show a good anti-tumor effect. This review summarizes the current research progress on the regulation and mechanism of proteasome subunits in promoting the occurrence and development .

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCell Line, TumorCell ProliferationHumansProteasome Endopeptidase ComplexSignal TransductionSTAT3 Transcription FactorProteasome Endopeptidase ComplexSTAT3 Transcription FactorHepatocellular carcinomaMechanismProteasomeProteasome core particleProteasome regulatory particleReview

Identifiers

PMID34402263
PMCPMC8710273
OpenAlexW3186174127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.